Status:
COMPLETED
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
Lead Sponsor:
Shire
Conditions:
Cytomegalovirus Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem ce...
Detailed Description
Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug wi...
Eligibility Criteria
Inclusion
- Allogeneic stem cell transplant recipient
- Recipient or donor CMV seropositive
- Have transplant engraftment
- Able to swallow tablets
Exclusion
- CMV organ disease
- HIV infection
- Use of other anti-CMV therapy post-transplant
Key Trial Info
Start Date :
December 13 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 23 2009
Estimated Enrollment :
681 Patients enrolled
Trial Details
Trial ID
NCT00411645
Start Date
December 13 2006
End Date
May 23 2009
Last Update
June 11 2021
Active Locations (97)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arkansas Myeloma Institute
Little Rock, Arkansas, United States, 72205
2
City of Hope Medical Center
Duarte, California, United States, 91010
3
Scripps Green Hospital
La Jolla, California, United States, 92037
4
UCSD Moores Center
La Jolla, California, United States, 92093-0960